

Average Proteinuria Grade Combined SLE Experiments +/- SEM




FIGURE 1

2 of 5

Dosing Protocol

SLE-6 Treatment, 3x/wk, Subcutaneously		Age (weeks)																	
		25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40		
A	5 mg/kg Rapamycin (AY-22989-21)	→																	
B	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
C	5 mg/kg Rapamycin (AY-22989-21)	→																	
	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
D	5 mg/kg Rapamycin (AY-22989-21)	→																	
E	5 mg/kg Rapamycin (AY-22989-21)	→																	
	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
F	200 ug/ms anti-murine IL-12	→																	
G	Vehicle	→																	

FIGURE 2

97 JPS-002 SLE-7 Histopathologic Evaluation of NZB x NZW F1 Hybrid Female Mice

42 weeks of age

Group	Animal	Spleen	Spleen	Kidney	Kidney	Kidney
No Therapy		Lymphoid Hyperplasia	Hematopoiesis	Interstitial Inflammation	Glomerulonephritis Cellularity- Membrane Thickness	Tubular Dilatation
	1	-2	-3	+2	-2 +2	+3
	2	+2	+2	+3	-1 +3	+3
	3	+2	+2	+2	-1 +3	+2
	4	+2	+2	+3	-3 +3	+4
	5	+2	+3	+3	-3 +3	+4
	Mean	+1.2	+1.2	+2.6	-2.0 +2.8	+3.2

Rapamycin

(Treatment Weeks 29-36)

1	+1	+1	(+1)	0	+1	+1
2	+1	+1	(+1)	0	+1	0
3	+1	+1	(+2)	0	0	0
4	+1	+1	0	0	0	0
5	+1	+1	(+1)	0	0	0
Mean	+1.0	+1.0	+1.0	0	+0.4	+0.2


Histologic Grades

- 0 = Normal
- 1 = Slight
- 2 = Mild
- 3 = Moderate
- 4 = Marked
- 5 = Severe
- () = Focal not Diffuse

Histopathologic Assessment : Elizabeth Goad, PhD, DVM.

FIGURE 3

A 95



Early Rapamycin given
beginning @ 25 weeks old.

Late Rapamycin given
beginning @ 33 weeks old.

- | | |
|---------------------------|--------------------------|
| (A) Early Rapa | (E) Anti-B7s + Late Rapa |
| (B) Anti-B7s | (F) Anti-IL-12 |
| (C) Anti-B7s + Early Rapa | (G) No Therapy |
| (D) Late Rapa | |

FIGURE 4A

B. Average Proteinuria Grade




FIGURE 4B

A.

Single Therapeutic Dosing




FIGURE 5A

B.

Combined Therapeutic Dosing




FIGURE 5B